MASLD is a common liver condition driven by obesity and metabolic dysfunction. Losing 10% of body weight can reverse liver damage, and GLP-1 drugs like semaglutide help many achieve this. Learn how weight loss and new medications work together to heal the liver.
Learn More
Tirzepatide (Zepbound) is a dual incretin therapy that activates GLP-1 and GIP receptors to promote significant weight loss. It outperforms older drugs like semaglutide, with users losing over 20% of body weight on average. Learn how it works, its side effects, and who it’s right for.
Learn More